An observational study in Biliary Atresia, Choledochal Cyst and Intrahepatic Cholestasis, sponsored by Nanjing Children's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 15 Days to 6 Months. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Nanjing Children's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Biliary Atresia with a site in China — 7 open to participants now, 9 under way, 1 of them phase 3. Biliary Atresia · China.
Among the 21 studies in Biliary Atresia with a site in China, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2026, is one of 10 observational ones, and was the 21st registered.
78 studies on the registry are indexed under Biliary Atresia; 26 are open to participants now.
Browse Biliary Atresia studies →7 of the 21 studies in Biliary Atresia with a site in China are open now. Recruiting first, the newest first:
Tongji Hospital · Sites in China
Ages 1 days–3 mo
Children's Hospital of Fudan University · Sites in China
Children's Hospital of Fudan University · Sites in China
Ages 14 days–90 days
Children's Hospital of Fudan University · Sites in China
Ages up to 3 mo
Weibing Tang · Sites in China
Ages 6 mo–6 yrs
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.
This study: 15 Days to 6 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 2
First in 2014; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 120 across 33 observational studies indexed under Biliary Atresia.
Median enrollment 160 across the 11 interventional studies, 200 across the 10 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 21 have an industry lead sponsor. The 10 most frequent:
Nanjing Children's Hospital is the lead sponsor of 17 studies on the registry; 5 are open to participants now.
Nanjing Children's Hospital has 2 studies filed under Biliary Atresia — fewer than ten, so there is no comparison to draw.
1 of the studies in Biliary Atresia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07940543Nanjing Children's HospitalConstruction of a Liver Metabolic Atlas in Biliary Atresia Based on Raman Spectroscopic Imaging | 2027-03-10 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Biliary Atresia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intra- and extrahepatic bile ducts. Although Kasai portoenterostomy can restore bile drainage, more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction but a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on serum liver function tests and semi-quantitative histological scoring, which cannot reveal the overall metabolic landscape or spatial heterogeneity of the liver. Raman imaging is a label-free, high-spatial-resolution molecular vibrational imaging technique that can simultaneously detect lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products. It has demonstrated metabolic phenotyping capability in tumor heterogeneity, organ development, and nonalcoholic fatty liver disease. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and metabolic boundaries of fibrous septa-remains unexplored by conventional metabolomics. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming that forms characteristic Raman-capturable metabolic signatures, which may serve as novel tools for disease stratification and prognosis prediction. This study aims to construct a Raman-based liver metabolic atlas and evaluate its prognostic value.
Biliary atresia (BA) is a severe infantile cholangiopathy characterized by progressive inflammation and fibrotic obliteration of the intrahepatic and extrahepatic bile ducts. Kasai portoenterostomy can temporarily restore bile drainage, but more than 50% of affected infants still progress to end-stage liver disease and require liver transplantation. BA is not merely a structural biliary obstruction; it is a complex liver disease involving cholestasis, oxidative stress, mitochondrial dysfunction, lipid peroxidation, bile acid metabolic disorders, and collagen deposition. Current clinical assessment relies mainly on conventional serum liver function indices (ALT, AST, GGT, TBIL, DBIL, and TBA) and semi-quantitative histopathological scoring. These approaches cannot reveal the overall metabolic landscape or the spatial heterogeneity of the liver, resulting in a lack of systematic understanding of metabolic reprogramming in BA.
Raman imaging is a label-free molecular vibrational spectroscopic imaging technique based on inelastic scattering. It can simultaneously detect chemical bond information from lipids, proteins, nucleic acids, glycogen, collagen, bilirubin, bile acids, and oxidative stress products without exogenous probes or labels, and it offers high spatial resolution and non-destructive detection. Raman imaging has demonstrated metabolic phenotyping capability in tumor metabolic heterogeneity, organ development, and nonalcoholic fatty liver disease. Previous studies suggest that BA patients have multiple metabolic abnormalities, including bile acid metabolic disorders. However, the in situ spatial distribution of metabolites in BA liver-especially metabolic differences among portal, parenchymal, and centrilobular regions, the metabolic microenvironment around bile duct reaction foci, and the metabolic boundaries of fibrous septa-cannot be obtained by conventional metabolomics, representing an important research gap. Raman imaging has the unique advantage of "spatial metabolomics," enabling metabolic information to be localized to specific pathological structures and providing a new dimension for understanding the relationship between intrahepatic metabolic heterogeneity and disease progression. Preliminary studies by our group have identified collagen deposition, oxidative stress, and bile acid metabolic abnormalities in BA liver. We hypothesize that BA liver undergoes coordinated metabolic reprogramming during pathological progression, forming characteristic Raman-capturable metabolic signatures that can comprehensively quantify multidimensional metabolic features and serve as novel tools for disease stratification and prognosis prediction.
Briefly, this single-center prospective observational study will enroll 60 infants with BA undergoing Kasai portoenterostomy and 20 age-matched controls (10 choledochal cysts and 10 intrahepatic cholestasis without BA). Intraoperative liver tissues will be collected and analyzed by confocal Raman imaging with near-infrared excitation and large-area multi-region scanning. HE and Masson staining and image registration will link spectral pixels to histological structures. A full-spectrum database will be established, and spectral unmixing will generate spatial metabolic heat maps, regional metabolic fingerprints, and metabolic gradients. Raman-derived parameters will be integrated with clinical and pathological data to develop a metabolic classification and a prognostic model for native liver survival using Cox and LASSO regression. Participants will be followed for at least 3 years. Primary outcomes are jaundice clearance and native liver survival after Kasai surgery; secondary outcomes include postoperative biochemical indices and liver stiffness. The study poses minimal risk, involves no new drugs or devices, and will be conducted with informed consent and ethical approval.
Patients with biliary atresia and undergoing Kasai surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biliary atresia patients who undergo Kasai surgery
Diagnostic Test: Stimulated Raman Test
All the intraoperative liver biopsy tissues of the participants will undergo Raman imaging to assess the metabolic status of the liver tissues.
Juandice clearance
Serum direct bilirubin \< 2mg/dL
Time frame: 3 months post Kasai augery
Native liver survival
Native liver survival without liver transplantation or death
Time frame: 2 years post Kasai augery
Plan to share: Yes — De-identified individual participant data (including demographic, clinical, and outcome variables) collected during the trial will be made available to qualified researchers.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will become accessible:Starting Date: 6 months after study completion;End Date: Minimum 5 years after publication.
Access criteria: Access to IPD requires submitting a formal research proposal (including hypothesis/analysis plan, ethical approval proof if applicable, and conflict of interest disclosure) to the investigator's email, along with a signed Data Use Agreement (DUA) prohibiting re-identification, commercial use, and redistribution.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing Children's Hospital